Delta-Fly Pharma, Inc.
Notice Regarding Monthly Exercise Status of the 12th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued by Third-Party Allotment
Publication of monthly exercise status of stock acquisition rights. For the subject month, the number of shares delivered was 910,000 shares; 9,100 stock acquisition rights were exercised, representing an exercise ratio of 9.10% of total issued rights (unexercised at previous month-end: 50,200 units; month-end: 41,100 units). The exercise restriction ratio is 6.36%.
Key Figures
- Number of shares delivered in the subject month: 910,000 shares
- Number of stock acquisition rights exercised during the subject month: 9,100 units
- Unexercised stock acquisition rights (month-end): 41,100 units
AI要約
Overview of Monthly Exercise Status of Stock Acquisition Rights
This report summarizes the monthly exercise status for October 2026 of the 12th stock acquisition rights (with exercise price adjustment clause) issued by third-party allotment. The number of shares delivered in the subject month was 910,000 shares, of which the total number of stock acquisition rights actually exercised was 9,100 units (representing 9.10% of total issued stock acquisition rights). Unexercised units at the previous month-end were 50,200 units, decreasing to 41,100 units at month-end.
Exercise Status and Compliance with Regulations
Breakdowns by exercise date are disclosed, and the status concerning exercise restrictions is reported in accordance with Article 434 of the Listing Rules. The number of shares delivered in the subject month is 910,000 shares, the number of listed shares is 14,305,000 shares, and the exercise ratio related to exercise restrictions is 6.36%. The number of issued shares and treasury shares at the previous month-end was 19,285,000 shares (including 198 treasury shares).
Delta-Fly Pharma, Inc.
Company overview · Stock price · Financial data · All IR
